CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.